Retail sentiment for Sarepta stayed strong after the firm said an 8-year-old's death in Brazil was not linked to its Duchenne gene therapy, Elevidys. The FDA is investigating, but Brazil officials cited a viral infection. Despite EU rejection and a US shipment pause, sentiment was 'extremely bullish' as message volume surged 65%.